---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-035756"
form_type: "8-K"
ticker: "RCKT"
cik: "0001281895"
company_name: "ROCKET PHARMACEUTICALS, INC."
filed_at: "2024-08-05T23:59:59+00:00"
generated_at: "2026-05-31T12:59:46.540594+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Rocket Pharma H1 2024 net loss $131.7M; KRESLADI review ongoing, cash into 2026

## Summary
- Net loss of $131.7M ($1.40/sh) for H1 2024 vs $124.0M ($1.55/sh) for H1 2023.
- Cash, equivalents & investments $278.8M; runway expected into 2026.
- FDA requested additional CMC info for KRESLADI (LAD-I); working to support approval.
- Phase 2 pivotal enrollment ongoing for RP-A501 (Danon) and RP-L301 (PKD) initiated.
- EC granted orphan medicinal product designation for RP-A601 (PKP2-ACM); Phase 1 enrolling.

## SEC filing metadata
- accession: 0001140361-24-035756
- form_type: 8-K
- ticker: RCKT
- cik: 0001281895
- company_name: ROCKET PHARMACEUTICALS, INC.
- filed_at: 2024-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1281895/000114036124035756/0001140361-24-035756-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1281895/000114036124035756/ef20033571_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-035756
- JSON: https://secwatch.observer/filing/0001140361-24-035756.json
- Plain text: https://secwatch.observer/filing/0001140361-24-035756.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.